Approach to the thyroid cancer patient with extracervical metastases

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 3, 2010, Pages 987-993

  Haugen, Bryan R ^a   Kane, Madeleine A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; ETIDRONIC ACID TC 99M; FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 124; IODINE 131; LEVOTHYROXINE; PAMIDRONIC ACID; POLY(METHYL METHACRYLATE); RADIOACTIVE IODINE; RADIOISOTOPE; RECOMBINANT THYROTROPIN; SAMARIUM 153; SORAFENIB; STRONTIUM 89; SUNITINIB; TAXANE DERIVATIVE; THYROGLOBULIN; THYROTROPIN; TUMOR MARKER; ZOLEDRONIC ACID;

ADULT; AGED; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CASE REPORT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOSIMETRY; DRUG COST; DRUG TARGETING; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTHYROIDISM; IMAGING SYSTEM; KIDNEY FAILURE; KYPHOPLASTY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATIENT CODING; PATIENT MONITORING; PERCUTANEOUS VERTEBROPLASTY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; SALIVARY GLAND DISEASE; SECOND CANCER; SIDE EFFECT; SPINE METASTASIS; SPINE STABILIZATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

EID: 77749267722     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2305     Document Type: Article

References (32)

1. Lang B, Lo CY, Chan WF, Lam KY, Wan KY 2007 Restaging of differentiated thyroid carcinoma by the ed. 6 AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol 14:1551-1559
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics, 2009. CA Cancer J Clin 59:225-249
3. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon 3rd HR 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021
4. Sampson E, Brierley JD, LeL W, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110:1451-1456
5. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129:622-627
6. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
7. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568-1573
8. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505
9. Coleman RE 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
10. Muresan MM,Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M, Zarnegar R, Weryha G 2008 Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15:37-49
11. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A 2007 Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939-949
12. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
13. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323
14. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon 3rd HR 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744
15. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242
16. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10:261-268
17. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80:2041-2045
18. Robbins RJ, Driedger A, Magner J 2006 Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121-1130
19. Van Nostrand D, Wartofsky L2007 Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 3:807-822, vii-viii
20. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587-1591
21. Lee JJ, Chung JK, Kim SE, Kang WJ, Park do J, Lee DS, Cho BY, Lee MC2008 Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med 22:727-734
22. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937-941
23. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366-1372
24. Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, Larson SM 2007 Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 48:143-149
25. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645
26. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94: 1493-1499
27. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
28. Coleman RE 2008 Risks and benefits of bisphosphonates. Br J Cancer 98:1736-1740
29. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84:1586-1590
30. Gagey O, Court C, Ziad N, Schlumberger M 2001 [Pelvic and spinal giant metastases from thyroid carcinomas: report of 8 cases]. Rev Chir Orthop Reparatrice Appar Mot 87:579-584
31. Brierley JD, Tsang RW 2008 External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 37:497-509, xi
32. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803